Imiquimod for the treatment of basal cell or squamous cell carcinoma a review of clinical effectiveness and cost-effectiveness
The purpose of this review is to compare the clinical effectiveness and cost-effectiveness of imiquimod (IMQ) to other treatment modalities for the treatment of basal cell carcinoma (BCC) or squamous cell carcinoma (SCC). This report is the first in the series of three reports on IMQ. The following...
| Main Authors: | , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
September 11, 2017, 2017
|
| Edition: | Version: 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The purpose of this review is to compare the clinical effectiveness and cost-effectiveness of imiquimod (IMQ) to other treatment modalities for the treatment of basal cell carcinoma (BCC) or squamous cell carcinoma (SCC). This report is the first in the series of three reports on IMQ. The following two reports will be on actinic keratosis and genital warts |
|---|---|
| Physical Description: | 1 PDF file (29 pages) illustrations |